The short answer: low libido in perimenopause is common, it’s not “just in your head,” and the interventions with the strongest evidence are not the ones most women are offered first.
If your desire for sex has dropped during perimenopause and it bothers you, you are not alone—and you are not broken. A nationally representative study of over 5,000 Australian women aged 40–69 found that sexual dysfunction is highly prevalent starting in early perimenopause, with nearly one in five women experiencing problems related to arousal, desire, and sexual self-image . Among women in early perimenopause (defined by changes in menstrual flow accompanied by vasomotor symptoms), the prevalence of sexual dysfunction was twice that of premenopausal women .
The data is clear: this is a physiological transition, not a personal failing. But what actually helps is where the conversation often goes wrong.
Why Libido Drops in Perimenopause
Testosterone is often called the “male hormone,” but women produce it too—in the ovaries and adrenal glands—and it contributes to sexual motivation and arousal . Unlike estrogen and progesterone, which fluctuate wildly and then drop sharply during the menopausal transition, testosterone declines slowly and steadily over time, starting around age 30 . For some women, that gradual drop crosses a threshold where desire becomes distressingly low—a condition clinicians diagnose as hypoactive sexual desire disorder (HSDD), or more recently under the broader DSM-5 category of female sexual interest/arousal disorder (FSIAD) .
But hormones are only part of the picture. Vaginal dryness and discomfort from declining estrogen can make sex painful, which understandably reduces desire . Sleep disruption from night sweats, mood changes, and the sheer exhaustion of midlife competing demands all compound the problem . Research increasingly frames menopausal sexual desire as a biopsychosocial phenomenon—biology, psychology, and relationship context all matter .
What the Evidence Actually Supports
First: Address Physical Discomfort
If sex hurts, desire will not follow. Local vaginal estrogen is “transformative” for many women, significantly improving dryness and discomfort, and is suitable for most—including many women with a history of hormone-sensitive breast cancer, though that requires individual consultation . Vaginal moisturizers (water-based or coconut-oil-based) are a low-risk first step . This is not a libido treatment per se, but it removes a major barrier.
Hormone Therapy: Helpful, But Not a Libido Cure
Systemic hormone therapy (estrogen with or without progesterone) can improve overall wellbeing, energy, and sleep, which may indirectly support desire . A Cochrane review found that hormone therapy slightly improves sexual function in perimenopausal and recently postmenopausal women, largely by reducing genitourinary symptoms and sleep disturbance . But the effect on desire specifically is modest. HRT alone does not reliably restore libido .
Testosterone: The Strongest Evidence for Desire, With Caveats
This is where the evidence is most interesting—and most complicated.
Clinical trials of transdermal testosterone at physiological doses (approximating premenopausal female levels) have demonstrated improvements in sexual desire, frequency of satisfying sexual events, and reduced distress compared with placebo in women with HSDD . An international consensus concluded that the only evidence-based indication for testosterone therapy in women is treatment of HSDD, with moderate benefit . The Endocrine Society and other bodies support a short-term trial (typically at least 6 months) for appropriately selected women .
The complications: No FDA-approved testosterone product exists for women in the United States . Clinicians prescribe off-label, often adapting male formulations at roughly one-tenth the dose, or using compounded creams and gels . Compounded products are not FDA-regulated in the same way, so dosing and quality can vary . Pellets are particularly controversial due to inconsistent dosing and inability to adjust if levels run high . Long-term safety data in women is lacking, though short-term studies show no increased cardiovascular risk .
In the UK, access is described as a “postcode lottery,” with no licensed female testosterone product currently available on the NHS . A product called Androfeme (available in Australia) is anticipated to seek UK licensing, which could improve access—but as of now, it remains uncertain .
The bottom line on testosterone: It works for some women with HSDD, but it requires careful patient selection, physiological dosing, monitoring, and a frank conversation about the limits of long-term safety data. It is not a casual add-on.
Psychological Interventions: More Effective Than You Might Expect
A 2026 systematic review and meta-analysis of 16 studies (n=1,445) examined psychological interventions for sexual concerns in perimenopausal and postmenopausal women. The pooled results showed significant improvements in sexual function . But the subgroup analysis revealed something counterintuitive: cognitive-behavioral therapy (CBT) and mindfulness-based interventions showed no to small effects when assessed as secondary outcomes. Education programs and counseling showed large effects .
The authors cautioned that the CBT and mindfulness studies didn’t directly target sexual concerns—they measured sexual function as a secondary outcome . A separate small trial of a four-session CBT protocol specifically designed for peri/postmenopausal sexual concerns found significant improvements in multiple domains of sexual function, body image, couple satisfaction, and reductions in menopause symptoms, depression, and anxiety—with 100% of participants reporting they were “very satisfied” . That trial was small, but it suggests that targeted psychological intervention, not generic therapy, is what matters.
A practical takeaway: counseling or structured education about what’s happening to your body and your sexuality during this transition may be more helpful than you’d expect. Feeling informed and less alone is not a placebo.
The Relationship Question
Before hormones, before testosterone, one clinician asks a blunt question: How is your relationship? . Do you still feel attracted to your partner? Are you making time for each other, or has life become “too busy and exhausting”? For many midlife women, competing demands leave little energy for intimacy, and if emotional connection has diminished, libido will not feel strong . Rebuilding connection—through communication, shared time, or deliberate date nights—is not a substitute for medical treatment, but it’s a variable that no pill can fix.
What Doesn’t Have Strong Evidence
-
Flibanserin and bremelanotide are FDA-approved for HSDD in premenopausal women, not specifically for perimenopausal or menopausal women . They have serious side effects and are not first-line for this population.
-
“Hormone balancing” supplements and proprietary blends marketed for libido have no robust clinical trial evidence supporting their use for HSDD.
A Practical Framework
If low libido is bothering you, the evidence suggests a stepped approach:
-
Rule out and address physical discomfort first. Vaginal dryness and pain are treatable and often overlooked .
-
Assess sleep, stress, and relationship context. These are not “soft” factors—they are drivers .
-
Consider systemic HRT if you have other menopausal symptoms. It may improve overall wellbeing and indirectly support desire, but don’t expect it to be a libido drug .
-
Ask specifically about HSDD and testosterone. If distress about low desire persists despite the above, a conversation with a menopause specialist about a monitored trial of transdermal testosterone at physiological doses is evidence-based, with the caveats about regulation and long-term data .
-
Consider targeted counseling or education. Not generic therapy—something specifically addressing sexual concerns in midlife .
Bottom line: Perimenopausal low libido is common, physiologically grounded, and treatable—but the treatments with the best evidence (physiological testosterone for HSDD, targeted counseling, addressing vaginal discomfort) are not the ones most women hear about first. You don’t have to accept it as an inevitable part of aging. But you do need a clinician who knows the difference between “just menopause” and a treatable sexual concern.